20 Sep 2021 14:50
IN BRIEF: Evgen Pharma's SFX-01 effective on tumour cells
IN BRIEF: Evgen Pharma's SFX-01 effective on tumour cells
Read more
- Home
- Share Prices
- AQSE Share Prices
- Euronext
- Stock Screeners
- Share Chat
- FX
- News & RNS
- Events
- Media
- Trading Brokers
- Finance Tools
- Members
Latest Share Chat
EVG.L Share News (EVG)
EVG Share
Price
EVG Share
News
EVG Share
Chat
EVG Share
Trades
EVG
Live RNS
EVG Share
Charts
EVG Broker
Ratings
EVG Directors
Deals
EVG Financial
Diary
EVG
Fundamentals
EVG Short
Positions
EVG
Media
EVG.L Information
- There is currently no data for EVG
Watchlists are a member only feature
Login to your account
Don't have an account? Click here to register.Friday broker round-up
Fri, 27th Jul 2018 13:14
(Sharecast News) - William Hill: Peel Hunt upgrades to hold with a target price of 305p.Tekmar group: Berenberg reiterates buy with a target price of 200p.NCC Group: Berenberg upgrades to buy with a target price of 260p.ASOS: Berenberg reiterates buy with a target price of 8,300p.Computacenter: Berenberg reiterates buy with a target price of 1,850p.Intu Properties: Liberum downgrades to sell with a target price of 145p.BHP Billiton: Liberum reiterates sell with a target price of 1,300p.ITV: Liberum reiterates buy with a target price of 275p.Indivior: Numis upgrades to buy with a target price of 380p.Morgan Advanced Materials: Numis reiterates add with a target price of 395p.Polymetal International: Numis reiterates buy with a target price of 1,000p.Howden Joinery: Canaccord downgrades to hold with a target price of 525p.Evgen Pharma: Northland Capital Markets reiterates buy with a target price of 113p.Compass Group: Berenberg reiterates buy with a target price of 1,800p.British American Tobacco: Berenberg reiterates buy with a target price of 4,950p.Croda International: Berenberg reiterates buy with a target price of 5,300p.Rightmove: UBS reiterates sell with a target price of 4,900p.Reckitt Benckiser: UBS reiterates neutral with a target price of 6,000p.BP: UBS reiterates neutral with a target price of 610p.
More News
2 Sep 2021 11:56
IN BRIEF: Evgen SFX-01 granted orphan drug designation by US FDA
IN BRIEF: Evgen SFX-01 granted orphan drug designation by US FDA
Read more13 Jul 2021 15:36
Evgen pleased with preclinical data on SFX-01
(Sharecast News) - Clinical-stage drug development company Evgen Pharma announced preclinical data demonstrating that 'SFX-01' was effective in in-vitro models of certain blood cancers on Tuesday.
Read more13 Jul 2021 14:09
IN BRIEF: Evgen Pharma files brain tumour treatment request with FDA
IN BRIEF: Evgen Pharma files brain tumour treatment request with FDA
Read more13 Jul 2021 11:25
IN BRIEF: Evgen Pharma encouraged by early data for SFX-01
IN BRIEF: Evgen Pharma encouraged by early data for SFX-01
Read more13 Jul 2021 11:20
AIM WINNERS & LOSERS: Star Phoenix wins new deal; Ebiquity revenue up
AIM WINNERS & LOSERS: Star Phoenix wins new deal; Ebiquity revenue up
Read more9 Jul 2021 11:51
Evgen Pharma halts trial as SFX-01 drug fails to help Covid patients
Evgen Pharma halts trial as SFX-01 drug fails to help Covid patients
Read more9 Jul 2021 10:52
AIM WINNERS & LOSERS: Evgen disappointed as SFX-01 flops study hurdle
AIM WINNERS & LOSERS: Evgen disappointed as SFX-01 flops study hurdle
Read more9 Jul 2021 10:33
Evgen 'surprised and disappointed' by findings in SFX-01 trial
(Sharecast News) - Clinical-stage drug development company Evgen Pharma announced the results of the interim safety and futility assessment readout of the first 100 patients treated in the 'STAR' Covid-19 trial of its lead asset, 'SFX-01', on Friday.
Read more6 Jul 2021 16:10
UK shareholder meetings calendar - next 7 days
UK shareholder meetings calendar - next 7 days
Read more15 Jun 2021 14:42
TRADING UPDATES: GB Group rebuilds dividend; IPF ups 2021 profit view
TRADING UPDATES: GB Group rebuilds dividend; IPF ups 2021 profit view
Read more14 Jun 2021 13:19
TRADING UPDATES: Synectics loss narrows; Active Energy loss widens
TRADING UPDATES: Synectics loss narrows; Active Energy loss widens
Read more14 Jun 2021 11:00
Evgen upbeat on new data on potential breast cancer treatment
(Sharecast News) - Clinical-stage drug development company Evgen Pharma announced new preclinical data on Monday, which showed 'SFX-01' could be of benefit to metastatic breast cancer (mBC) patients who had become resistant to CDK4/6 inhibitors.
Read more26 Apr 2021 13:02
IN BRIEF: Evgen Pharma appoints Huw Jones as chief medical officer
IN BRIEF: Evgen Pharma appoints Huw Jones as chief medical officer
Read more7 Apr 2021 16:22
IN BRIEF: Evgen Pharma notes publication on sulforaphane in Covid-19
IN BRIEF: Evgen Pharma notes publication on sulforaphane in Covid-19
Read more